Trial reportInternational journal of colorectal disease2025
Obsidian®ASG in anastomotic healing after rectal cancer resection-OBANORES: a prospective clinical feasibility study.
Trial report in International journal of colorectal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Impact of problem management-guided health education with positive incentive nursing after rectal cancer surgery.World journal of gastrointestinal surgery · 2025Trial
- Platelet-rich fibrin matrix as treatment for complex anal fistulae: A 3-year experience at a tertiary centre.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026Article
- Multidisciplinary collaborative enhanced recovery after surgery nursing in patients with colorectal cancer: A comparative study.World journal of gastrointestinal oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeAnastomotic leakage following rectal cancer resection is a serious complication. Despite efforts to prevent it, the risk remains high. Obsidian®ASG, an AUTOLOGOUS fibrin matrix with thrombocytes derived from the patient's blood, shows promise but has not been thoroughly tested in rectal anastomosis. The aim of this study was to assess the feasibility of using Obsidian®ASG as a supplement in rectal anastomosis creation during minimally invasive rectal cancer resection.
methodsThis prospective IDEAL stage 2a development cohort study included 50 patients undergoing rectal cancer resection with anastomosis using minimally invasive surgery at Aarhus University Hospital, Denmark. Obsidian®ASG application was assessed using a predefined rating scale: "Complete" (applied in all three prescribed steps), "Almost complete" (applied in at least the first or second step), and "Incomplete" (all others). Feasibility required "Complete" or "Almost complete" application in at least 90% of patients.
resultsObsidian®ASG application was "Complete" in 15 cases (30%) and "Almost complete" in 35 cases (70%), meeting feasibility criteria in all patients. No "Incomplete" applications occurred. Difficulties in achieving "Complete" application included anatomical constraints, material depletion, machine error, and time constraints.
conclusionObsidian®ASG was successfully applied in all patients undergoing minimally invasive rectal cancer surgery. These findings suggest its feasibility, but further large-scale, multi-center randomized trials are needed to fully assess its potential benefits for patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.